Johnson & Johnson halts mid-stage trial of experimental eczema drug (2025-12-26)
Johnson & ⁠Johnson said ‍it ‍discontinued ‌a ‌mid-stage study ​of its experimental drug ⁠to treat atopic dermatitis, after it ‍failed to ‌meet ⁠efficacy goals.